Skip to main content
. 2007 Jan 23;96(3):485–491. doi: 10.1038/sj.bjc.6603581

Table 2. Correlation of HER2/neu, cytoplasmic or nuclear CXCR4 expression, and SDF-1 abundance with clinicopathologic characteristics.

  HER2/neu
CXCR4
SDF-1
            Cytoplasmic
Nuclear
         
  1 a 2 3 N P 1 2 3 N P Yes/no P 1 2 3 N P
Malignity         NSb         NSb   NSc         NSb
 Borderline 17 3 0 20   9 8 1 15   5/15   12 6 1 19  
 Malignant 92 31 4 127   55 51 13 119   22/101   87 30 11 128  
                                   
Histology (malignant)         NSb         NSb   NSb         NSb
 Serous 52 14 3 69   25 34 6 65   10/55   46 17 7 70  
 Endometrioid 18 5 1 24   10 9 4 23   5/20   15 6 3 24  
 Mucinous 6 1 0 7   3 3 0 6   4/6   6 1 0 7  
 Clear cell 5 2 0 7   5 1 0 6   1/5   6 1 0 7  
 Mixed 5 3 0 8   4 2 1 7   1/4   5 2 1 8  
 Undifferentiated 6 6 0 12   8 2 2 12   1/11   9 3 0 12  
                                   
FIGO stage         NS                        
          NS (0.064)d         NSd   NSd         NSd
 1 42 9 0 51   18 23 5 46   11/41   33 11 6 50  
 2 12 2 0 14   8 4 0 12   2/10   9 5 0 14  
 3 51 20 3 74   33 30 8 71   14/58   53 17 5 75  
 4 4 3 1 8   5 2 1 8   0/7   4 3 1 8  
                                   
Grade (w/o borderline)         NSb         NSb   NSb         NSb
 G1 18 3 0 21   6 9 3 18   6/16   12 7 2 21  
 G2 18 7 1 26   12 11 2 25   6/20   20 3 3 26  
 G3 46 21 2 69   31 28 7 66   7/55   47 19 4 70  
a

For consistency with our rating system, HER2/neu scores were translated as follows: ‘0’ and ‘1+’=‘1’, ‘2+’=‘2’, and ‘3+’=‘3’.

b

Pearson's χ2 test (corrected).

c

Fisher's exact test (corrected).

d

Spearman's correlation test, corrected for multiple testing.

Abbreviations: NS=not significant, FIGO=International Federation of Gynecology and Obstetrics.